(Q38020037)

27 August 2017

title

Biologic therapy in psoriasis: perspectives on associated risks and patient management (English)

1 reference

27 August 2017

Kim A Papp

1

1 reference

27 August 2017

Joel Dekoven

2

1 reference

27 August 2017

Laurie Parsons

3

1 reference

27 August 2017

Syed Pirzada

4

1 reference

27 August 2017

Michael Robern

5

1 reference

27 August 2017

Lynne Robertson

6

1 reference

27 August 2017

Jerry K L Tan

7

1 reference

27 August 2017

publication date

1 May 2012

1 reference

Journal of cutaneous medicine and surgery

27 August 2017

published in

1 reference

27 August 2017

volume

16

1 reference

27 August 2017

issue

3

1 reference

27 August 2017

page(s)

153-168

1 reference

The treatment of moderate-to-severe psoriasis: prescreening and monitoring psoriatic patients on biologics

27 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Practical aspects of prescribing a biologic

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Granulomatous infectious diseases associated with tumor necrosis factor antagonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three-year prospective French Research Axed on Tolerance of Biotherapies registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2)

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Improvement in quality of life with infliximab induction and maintenance therapy in patients with moderate-to-severe psoriasis: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Infliximab induction therapy for patients with severe plaque-type psoriasis: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Tumour necrosis factor antagonists: structure, function, and tuberculosis risks

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Association of methotrexate and tumour necrosis factor antagonists with risk of infectious outcomes including opportunistic infections in the CORRONA registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Hepatitis B reactivation in a chronic hepatitis B surface antigen carrier with rheumatoid arthritis treated with infliximab and low dose methotrexate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Effect of tumour necrosis factor antagonists on serum transaminases and viraemia in patients with rheumatoid arthritis and chronic hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Risk of Herpes Zoster in Patients With Rheumatoid Arthritis Treated With Anti–TNF-α Agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Population-based study of autoimmune conditions and the risk of specific lymphoid malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor alpha therapies: does the risk change with the time since start of treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Lymphoma in patients treated with anti-TNF: results of the 3-year prospective French RATIO registry

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Cardiovascular risk factors in high-need psoriasis patients and its implications for biological therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

The risk of stroke in patients with psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Patients with severe psoriasis are at increased risk of cardiovascular mortality: cohort study using the General Practice Research Database

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Therapy Insight: managing cardiovascular risk in patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Tumor necrosis factor-alpha antagonist use and heart failure in elderly patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

No evidence of association between anti-tumor necrosis factor treatment and mortality in patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Cardiovascular, rheumatologic, and pharmacologic predictors of stroke in patients with rheumatoid arthritis: a nested, case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Beneficial effect of 1-year etanercept treatment on the lipid profile in responding patients with rheumatoid arthritis: the ETRA study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failu

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Long-term course of demyelinating neuropathies occurring during tumor necrosis factor-alpha-blocker therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Effectiveness of the combination of a whole-blood interferon-gamma assay and the tuberculin skin test in detecting latent tuberculosis infection in rheumatoid arthritis patients receiving adalimumab therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Lymphoma risk in psoriasis: results of the PUVA follow-up study

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

National Psoriasis Foundation clinical consensus on psoriasis comorbidities and recommendations for screening.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Canadian Cardiovascular Society Consensus Conference guidelines on heart failure, update 2009: diagnosis and management of right-sided heart failure, myocarditis, device therapy and recent important clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Hepatitis B virus (HBV) reactivation with immunosuppressive therapy in rheumatic diseases: assessment and preventive strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Clinical presentation of acute viral hepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Patients with rheumatoid arthritis undergoing surgery: how should we deal with antirheumatic treatment?

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Infectious and healing complications after elective orthopaedic foot and ankle surgery during tumor necrosis factor-alpha inhibition therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Perioperative management of patients with rheumatoid arthritis in the era of biologic response modifiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Vaccinations in patients with immune-mediated inflammatory diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F120347541201600305

10.1177/120347541201600305

21 January 2018

Identifiers

DOI

1 reference

27 August 2017

1 reference